Akademik Veri Yönetim Sistemi
25th Annual Meeting of the European Society for Clinical Virology (ESCV) , Milan, İtalya, 30 Ağustos - 02 Ekim 2023, cilt.1, sa.1, ss.105
BACKGROUND-AIM
The Bio-Speedy Meningitis/Encephalitis (ME) (Bioeksen, Istanbul, Turkey) panel is a multiplex PCR test aiming for the simultaneous,
rapid (∼1-h) detection of 17 pathogens (E. coli K1, H. influenzae, L. monocytogenes, N. meningitidis, S. pneumoniae, S. agalactiae,
CMV, Enterovirus (EV), HSV-1 and 2, HHV-6, HPeV, VZV and Cryptococcus gatti/neoformans) from cerebrospinal fluid (CSF)
specimens for in vitro diagnosing of CNS infections.
This study evaluated the Bio-Speedy ME panel’s performance in a single center.
METHODS
This study included CSF specimens of 88 patients with suspected CNS infection between June 2022 and March 2023. The results of
the Bio-Speedy panel were compared with gram staining/bacterial culture and the FTD Viral meningitis Kit (Fast Track Diagnostics
Ltd, Luxemburg) (CE-marked for IVD use in the EU) (HSV-1, HSV-2, VZV, EV, Mumps virus, HPeV). Nucleic acid purification of viruses
was performed with the EZ1&2 Virus Mini Kit (Qiagen, Germany) in the EZ1 system.
Test results supported by clinical/radiologic findings and CSF cell count [UF-5000 flow cytometry system (Sysmex, Japan)] were
interpreted as true positive (TP), and inconsistent results were interpreted as indeterminate positives in terms of clinical diagnosis
(IP).
RESULTS
At least one pathogen was detected by at least one method in 16 (18.2%) samples, of which 12 (13.6%) were considered TP.
Nine of them [VZV (n=3), EV (n=1), S.pneumoniae (n=2), N. meningitides (n=1), H. influenzae (n=1)] were detected by Biospeedy
panel, four of them were detected by FTD and also BioSpeedy panels [VZV (n=3), EV (n=1)]. One bacteria grew only in the culture
(S.pyogenes), and two viruses were detected only by the FTD panel (HSV-2 and Mumps virus).
A total of five pathogens [S. pneumoniae (n=2), HHV-6 (n=2), HHV-7 (n=1)] detected only by Biospeedy were considered IP.
CONCLUSIONS
The Biospeedy molecular diagnostic panel includes a wide range of possible pathogens on a broad scale to avoid false negative
results and ensure an accurate diagnosis. However, test results should be interpreted or confirmed according to clinical and laboratory
examination -especially bacteria- to avoid method-induced IP results and unnecessary treatment applications.